Analysis of cross-resistance of the selective estrogen receptor modulators arzoxifene (LY353381) and LY117018 in tamoxifen-stimulated breast cancer xenografts

Clinical Cancer Research

Volumn 7, Issue 8, 2001, Pages 2505-2512

  MacGregor Schafer, Jennifer ^a   Lee, Eun Sook ^a,b   Dardes, Rita C ^a   Bentrem, David ^a   O’Regan, Ruth M ^a   de Los Reyes, Alexander ^a   Jordan, V Craig ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

^b National Cancer Center   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

6 HYDROXY 2 (4 HYDROXYPHENYL) 3 [4 [2 (1 PYRROLIDINYL)ETHOXY]BENZOYL]BENZO[B]THIOPHENE; ARZOXIFENE; ESTRADIOL; RALOXIFENE; TAMOXIFEN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER GROWTH; CONTROLLED STUDY; CROSS RESISTANCE; DRUG STRUCTURE; FEMALE; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; BREAST NEOPLASMS; DRUG RESISTANCE, NEOPLASM; ESTRADIOL; FEMALE; HUMANS; MICE; MICE, NUDE; PIPERIDINES; PYRROLIDINES; SELECTIVE ESTROGEN RECEPTOR MODULATORS; TAMOXIFEN; THIOPHENES; TIME FACTORS; TREATMENT OUTCOME; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 0034890567     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (54)

1. Tamoxifen in the treatment of breast cancer
2. Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study
3. Tamoxifen for early breast cancer: An overview of the randomised trials
4. Clinical significance of tamoxifen withdrawal response
5. Response after withdrawal of tamoxifen and progestogens in advanced breast cancer
6. Tamoxifen-induced tumor stimulation and withdrawal response
7. Oestrogen receptor: A stable phenotype in breast cancer
8. Pharmacokinetics, pharmacological and anti-tumour effects of the specific antioestrogen ICI 182780 in women with advanced breast cancer
9. ARIMIDEX: A potent and selective aromatase inhibitor for the treatment of advanced breast cancer
10. Antiestrogen ICI 164, 384 reduces cellular estrogen receptor content by increasing its turnover
11. Uterine bioassay of tamoxifen, trioxifene and a new estrogen antagonist (LY117018) in rats and mice
12. Differential antiestrogen action in the immature rat uterus: A comparison of hydroxylated antiestrogens with high affinity for the estrogen receptor
13. Inhibition of the uterotropic activity of estrogens and antiestrogens by the short acting antiestrogen LY117018
14. Antagonism of estrogen action with a new benzothiophene derived antiestrogen
15. Effects of a new antiestrogen, keoxifene (LY156758), on growth of carcinogen-induced mammary tumors and on LH and prolactin levels
16. Antitumor actions of keoxifene and tamoxifen in the N-nitrosomethylurea-induced rat mammary carcinoma model
17. Chemoprevention of mammary carcinogenesis in the rat: Combined use of raloxifene and 9-cis-retinoic acid
18. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women
19. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: Results from a 3-year randomized clinical trial
20. The effect of raloxifene on risk of breast cancer in postmenopausal women: Results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation
21. Raloxifene hydrochloride
22. LY353381.HCl: A novel raloxifene analog with improved SERM potency and efficacy in vivo
23. A human cell line from a pleural effusion derived from a breast carcinoma
24. MCF-7: The first hormone-responsive breast cancer cell line
25. Effect of estrogens and antiestrogens on growth of human breast cancer cells in athymic nude mice
26. Development of tamoxifen-stimulated growth of MCF-7 tumors in athymic mice after long-term antiestrogen administration
27. Human breast cancer in the athymic nude mouse: Cytostatic effects of long-term antiestrogen therapy
28. Characterization of tamoxifen stimulated MCF-7 tumor variants grown in athymic mice
29. Growth suppression of human breast cancer cells by the introduction of a wild-type p53 gene
30. Database of p53 gene somatic mutations in human tumors and cell lines
31. Rapid development of tamoxifen stimulated mutant p53 breast tumors (T47D) in athymic mice
32. Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents
33. Antiestrogenic action of toremifene on hormone-dependent, -independent, and -heterogeneous breast tumor growth in the athymic mouse
34. Effects of the antiestrogens tamoxifen, toremifene, and ICI 182, 780 on endometrial cancer growth
35. Cross-resistance of triphenylethylene type antiestrogens but not ICI 182, 780 in tamoxifen-stimulated breast tumors grown in athymic mice
36. Selective oestrogen receptor modulation: Molecular pharmacology for the millennium
37. Diverse signaling pathways modulate nuclear receptor recruitment of N-CoR and SMRT complexes
38. Comparative analyses of mechanistic differences among antiestrogens
39. Silencing and reactivation of the selective estrogen receptor modulator-estrogen receptor α complex
40. Peptide antagonists of the human estrogen receptor
41. Thoughts on tamoxifen resistant breast cancer. Are coregulators the answer or just a red herring?
42. The partial agonist activity of antagonist-occupied steroid receptors is controlled by a novel hinge domain-binding coactivator L7/SPA and the corepressors N-CoR or SMRT
43. The key to the antiestrogenic mechanism of raloxifene is amino acid 351 (aspartate) in the estrogen receptor
44. The interaction of raloxifene and the active metabolite of the antiestrogen (SC5705) with the human estrogen receptor (ER)
45. Allosteric silencing of activating function 1 in the 4-hydroxytamoxifen estrogen receptor complex is induced by substituting glycine for aspartate at amino acid 351
46. Measurement of steroid hormone receptors in breast cancer patients on tamoxifen
47. Comparison of estrogen receptor DNA binding in untreated and acquired antiestrogen-resistant human breast tumors
48. Evidence for the metabolic activation of non-steroidal antioestrogens: A study of structure-activity relationships
49. Tamoxifen metabolites in patients on long-term adjuvant therapy for breast cancer
50. The pharmacology and clinical uses of tamoxifen
51. Phase I study of a third-generation selective estrogen receptor modulator, ly353381.hcl, in metastatic breast cancer
52. Paradoxical regulation of estrogen-dependent growth factor gene expression in estrogen receptor (ER)-negative human breast cancer cells stably expressing ER
53. The oestrogen-like effect of 4-hydroxytamoxifen on induction of transforming growth factor α mRNA in MDA-MB-231 breast cancer cells stably expressing the oestrogen receptor
54. Comparison of the effects of a pure steroidal antiestrogen with those of tamoxifen in a model of human breast cancer